Bio-Imaging Technologies Inc. said that it has agreed to assistAdria Laboratories in a Phase III trial of a diagnostic imagingagent in cancer patients. Bio-Imaging will use its proprietary,computer-assisted medical image processing technology to helpdetermine the effectiveness of Adria's radio-labeled imagingagent.
Hundreds of patients, with two kinds of cancer, are involved inthe study, Bio-Imaging said. The company would not releasemore specific information about the trial or financial terms ofthe agreement. Adria's injectable imaging agent allows thetumor to be seen in great detail, Bio-Imaging said.
(c) 1997 American Health Consultants. All rights reserved.